Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent IMRT with weekly paclitaxel + cisplatin followed by surgery in potentially resectable thymic tumors
ChiCTR2200057827Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in thymoma and thymic carcinoma (TC), sponsored by Shanghai Chest Hospital. Primary endpoints: Objective response rate and R0 resection rate. Started Mar 2022; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2200057827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057827.